Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus alone or with Lucentis in Neovascular AMD
NCT00857259Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of everolimus in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Feb 2009; status: terminated.
02
Drugs
everolimus
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00857259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00857259.